Efficacy and safety of platelet-rich plasma in the treatment of carpal tunnel syndrome: A network meta-analysis of different injection treatments
Purpose: Carpal tunnel syndrome (CTS) is a common form of median nerve compression in the wrist caused by focal peripheral neuropathy. Platelet-rich plasma (PRP) therapy could improve the healing ability by exposing the injured tissues to high concentrations of autologous growth factors. Our study a...
| Main Authors: | , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Frontiers Media S.A.
2022-11-01
|
| Series: | Frontiers in Pharmacology |
| Subjects: | |
| Online Access: | https://www.frontiersin.org/articles/10.3389/fphar.2022.906075/full |
| _version_ | 1798023027471941632 |
|---|---|
| author | Pan Hong Yu Zheng Saroj Rai Yuhong Ding Yeming Zhou Ruikang Liu Jin Li |
| author_facet | Pan Hong Yu Zheng Saroj Rai Yuhong Ding Yeming Zhou Ruikang Liu Jin Li |
| author_sort | Pan Hong |
| collection | DOAJ |
| description | Purpose: Carpal tunnel syndrome (CTS) is a common form of median nerve compression in the wrist caused by focal peripheral neuropathy. Platelet-rich plasma (PRP) therapy could improve the healing ability by exposing the injured tissues to high concentrations of autologous growth factors. Our study aims to compare all injective treatments for CTS and assess the efficacy and priority of PRP therapy.Methods: We searched Medline, Embase, Web of Science, Cochrane databases, and Clinicaltrial.gov until 17 October 2022. We only included data from randomized controlled trials (RCTs) that evaluated PRP injection therapy or drug injection therapy. The included RCTs measured at least one of the following three outcomes with validated instruments: in the visual analog scale (VAS), symptom severity scale (SSS), and functional status scale (FSS).Results: Overall, 19 studies with 1,066 patients were included in this study. We used the SUCRA rankings to determine the merits of various therapies. In all, 5% dextrose injections were the best treatment strategy for the VAS (MD −1.22, 95% CI −2.66 to 0.23; SUCRA = 79.2%), followed by triamcinolone (high-dose) injections (MD −0.69, 95% CI −2.11 to 0.73; SUCRA = 62.7%) and PRP injections (MD −0.39, 95% CI −1.67 to 0.89; SUCRA = 60.0%). In the SSS, the most effective intervention was hydroxyprogesterone injections (MD −0.62, 95% CI −1.09 to −0.16; SUCRA = 91.0%). The SUCRA ranking of PRP was second only to steroids and estrogen (MD −0.39, 95% CI −0.60 to −0.18; SUCRA = 60.8%). In the FSS, the best regimen strategy was hydroxyprogesterone injections (MD 0.12, 95% CI −0.30 to 0.54; SUCRA = 99.5%), followed by triamcinolone (low-dose) injections (MD −0.02, 95% CI −0.54 to 0.49; SUCRA = 87.4%) and PRP injections (MD −0.26, 95% CI −0.43 to −0.09; SUCRA = 77.1%).Conclusion: PRP is an alternative choice for CTS treatment. PRP injection is second only to steroids and estrogen in the treatment efficacy of CTS, with a wide indication and safe outcome. |
| first_indexed | 2024-04-11T17:39:36Z |
| format | Article |
| id | doaj.art-148cf165bed6463389a84ad726542c8c |
| institution | Directory Open Access Journal |
| issn | 1663-9812 |
| language | English |
| last_indexed | 2024-04-11T17:39:36Z |
| publishDate | 2022-11-01 |
| publisher | Frontiers Media S.A. |
| record_format | Article |
| series | Frontiers in Pharmacology |
| spelling | doaj.art-148cf165bed6463389a84ad726542c8c2022-12-22T04:11:31ZengFrontiers Media S.A.Frontiers in Pharmacology1663-98122022-11-011310.3389/fphar.2022.906075906075Efficacy and safety of platelet-rich plasma in the treatment of carpal tunnel syndrome: A network meta-analysis of different injection treatmentsPan Hong0Yu Zheng1Saroj Rai2Yuhong Ding3Yeming Zhou4Ruikang Liu5Jin Li6Department of Orthopaedic Surgery, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, ChinaBasic Medical School, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, ChinaDepartment of Orthopaedics and Trauma Surgery, Karama Medical Center, Dubai, United Arab EmiratesSecond Clinical School, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, ChinaBasic Medical School, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, ChinaDepartment of Endocrinology, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, ChinaDepartment of Orthopaedic Surgery, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, ChinaPurpose: Carpal tunnel syndrome (CTS) is a common form of median nerve compression in the wrist caused by focal peripheral neuropathy. Platelet-rich plasma (PRP) therapy could improve the healing ability by exposing the injured tissues to high concentrations of autologous growth factors. Our study aims to compare all injective treatments for CTS and assess the efficacy and priority of PRP therapy.Methods: We searched Medline, Embase, Web of Science, Cochrane databases, and Clinicaltrial.gov until 17 October 2022. We only included data from randomized controlled trials (RCTs) that evaluated PRP injection therapy or drug injection therapy. The included RCTs measured at least one of the following three outcomes with validated instruments: in the visual analog scale (VAS), symptom severity scale (SSS), and functional status scale (FSS).Results: Overall, 19 studies with 1,066 patients were included in this study. We used the SUCRA rankings to determine the merits of various therapies. In all, 5% dextrose injections were the best treatment strategy for the VAS (MD −1.22, 95% CI −2.66 to 0.23; SUCRA = 79.2%), followed by triamcinolone (high-dose) injections (MD −0.69, 95% CI −2.11 to 0.73; SUCRA = 62.7%) and PRP injections (MD −0.39, 95% CI −1.67 to 0.89; SUCRA = 60.0%). In the SSS, the most effective intervention was hydroxyprogesterone injections (MD −0.62, 95% CI −1.09 to −0.16; SUCRA = 91.0%). The SUCRA ranking of PRP was second only to steroids and estrogen (MD −0.39, 95% CI −0.60 to −0.18; SUCRA = 60.8%). In the FSS, the best regimen strategy was hydroxyprogesterone injections (MD 0.12, 95% CI −0.30 to 0.54; SUCRA = 99.5%), followed by triamcinolone (low-dose) injections (MD −0.02, 95% CI −0.54 to 0.49; SUCRA = 87.4%) and PRP injections (MD −0.26, 95% CI −0.43 to −0.09; SUCRA = 77.1%).Conclusion: PRP is an alternative choice for CTS treatment. PRP injection is second only to steroids and estrogen in the treatment efficacy of CTS, with a wide indication and safe outcome.https://www.frontiersin.org/articles/10.3389/fphar.2022.906075/fullcarpal tunnel syndromeplatelet-rich plasmacorticosteroidnetwork meta-analysisestrogen |
| spellingShingle | Pan Hong Yu Zheng Saroj Rai Yuhong Ding Yeming Zhou Ruikang Liu Jin Li Efficacy and safety of platelet-rich plasma in the treatment of carpal tunnel syndrome: A network meta-analysis of different injection treatments Frontiers in Pharmacology carpal tunnel syndrome platelet-rich plasma corticosteroid network meta-analysis estrogen |
| title | Efficacy and safety of platelet-rich plasma in the treatment of carpal tunnel syndrome: A network meta-analysis of different injection treatments |
| title_full | Efficacy and safety of platelet-rich plasma in the treatment of carpal tunnel syndrome: A network meta-analysis of different injection treatments |
| title_fullStr | Efficacy and safety of platelet-rich plasma in the treatment of carpal tunnel syndrome: A network meta-analysis of different injection treatments |
| title_full_unstemmed | Efficacy and safety of platelet-rich plasma in the treatment of carpal tunnel syndrome: A network meta-analysis of different injection treatments |
| title_short | Efficacy and safety of platelet-rich plasma in the treatment of carpal tunnel syndrome: A network meta-analysis of different injection treatments |
| title_sort | efficacy and safety of platelet rich plasma in the treatment of carpal tunnel syndrome a network meta analysis of different injection treatments |
| topic | carpal tunnel syndrome platelet-rich plasma corticosteroid network meta-analysis estrogen |
| url | https://www.frontiersin.org/articles/10.3389/fphar.2022.906075/full |
| work_keys_str_mv | AT panhong efficacyandsafetyofplateletrichplasmainthetreatmentofcarpaltunnelsyndromeanetworkmetaanalysisofdifferentinjectiontreatments AT yuzheng efficacyandsafetyofplateletrichplasmainthetreatmentofcarpaltunnelsyndromeanetworkmetaanalysisofdifferentinjectiontreatments AT sarojrai efficacyandsafetyofplateletrichplasmainthetreatmentofcarpaltunnelsyndromeanetworkmetaanalysisofdifferentinjectiontreatments AT yuhongding efficacyandsafetyofplateletrichplasmainthetreatmentofcarpaltunnelsyndromeanetworkmetaanalysisofdifferentinjectiontreatments AT yemingzhou efficacyandsafetyofplateletrichplasmainthetreatmentofcarpaltunnelsyndromeanetworkmetaanalysisofdifferentinjectiontreatments AT ruikangliu efficacyandsafetyofplateletrichplasmainthetreatmentofcarpaltunnelsyndromeanetworkmetaanalysisofdifferentinjectiontreatments AT jinli efficacyandsafetyofplateletrichplasmainthetreatmentofcarpaltunnelsyndromeanetworkmetaanalysisofdifferentinjectiontreatments |